Physician profile
John W Byron
NPI 1992769806
$1,351.31
in general payments reported to CMS, 2019-2025
17 companies · $166 in 2025
The $166 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $152 · 2020: $166 · 2021: $270 · 2022: $247 · 2023: $235 · 2024: $114 · 2025: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $515.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $290.73 | 2019-2023 | Lo Loestrin Fe, Orilissa |
| Avion Pharmaceuticals | $200.95 | 2019-2022 | |
| Exeltis, USA INC. | $157.94 | 2022-2025 | Slynd |
| Pfizer INC. | $135.89 | 2019-2023 | |
| Organon LLC | $118.49 | 2022-2025 | Nexplanon |
| Coopersurgical, INC. | $113.19 | 2022-2025 | Paragard T 380a, Paragard T 380a |
| Astellas Pharma US INC | $76.11 | 2025 | Veozah |
| Mayne Pharma Commercial LLC | $75.09 | 2022-2025 | |
| Therapeuticsmd, INC. | $40.32 | 2020-2021 | |
| Daiichi Sankyo INC. | $32.81 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.41 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $19.70 | 2025 | Gemtesa |
| Agile Therapeutics, INC. | $18.91 | 2021 | |
| Urovant Sciences INC | $16.89 | 2022 | |
| Novo Nordisk INC | $15.11 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Minerva Surgical, INC | $11.77 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Byron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.